Form 4: RELMADA Therapeutics Grants 400,000 Stock Options to CA and CO Chuck Ence

RELMADA Therapeutics, Inc. has granted 400,000 stock options to its Chief Accounting Officer and Chief Operating Officer, Chuck Ence, with an exercise price of $0.67, vesting quarterly over four years.

Summary

• Chuck Ence, the Chief Accounting Officer and Chief Operating Officer of RELMADA THERAPEUTICS, INC. (RLMD), was granted 400,000 stock options.
• The stock options have an exercise price of $0.67 per share.
• The grant date for these options was June 26, 2025.
• Vesting will occur in 16 equal quarterly installments, commencing on September 26, 2025.
• The options are exercisable until their expiration date of June 26, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with shareholder value creation, although it is a routine compensation event.

Positives

• The grant of 400,000 stock options to a key executive like Chuck Ence aligns management's interests with shareholder value creation.
• The exercise price of $0.67 provides an incentive for future stock price appreciation, benefiting both the executive and shareholders.

Negatives

• No explicit negatives are disclosed in this Form 4 filing, which primarily reports an insider stock option grant.

Risks

• This Form 4 primarily reports an insider transaction and does not detail specific company risks.

Future Outlook

The stock options granted to Chuck Ence will vest in 16 equal quarterly installments commencing on September 26, 2025, indicating a long-term incentive structure tied to future performance and executive retention.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

The granting of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, aiming to align management incentives with long-term shareholder value creation and retain talent.

Comparison to Industry Standards

• The grant of 400,000 stock options to a Chief Accounting Officer and Chief Operating Officer is a standard form of executive compensation, comparable to practices seen in other small to mid-cap biotechnology companies. Specific comparable companies or projects are not detailed in this filing.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this filing.

Related Party Transactions

• The grant of stock options to Chuck Ence, an officer of RELMADA THERAPEUTICS, INC., constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management incentives with long-term stock performance.
• Management: Direct positive impact through increased compensation and long-term incentives.

Next Steps

• The stock options will begin vesting in 16 equal quarterly installments starting September 26, 2025.

Key Dates

Keywords

RELMADA THERAPEUTICS, RLMD, stock options, insider transaction, executive compensation, Chuck Ence, Form 4, beneficial ownership